SELLAS Life Sciences Shares Are Trading Higher After the Company Was Granted FDA Rare Pediatric Disease Designation for Its SLS009 CDK9 Inhibitor for the Treatment of Pediatric Acute Lymphoblastic Leukemia, Making It Eligible for a Priority Review...
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.